Table A1. Features of 5 patients with Granulibacter bethesdensis infection*.

Patient no.	Age, y/sex	Country of origin	Radiographic findings	Pathologic findings (site)	Leukocytes, × 103 cells/μL†	ESR, mm/h†	Duration of signs and symptoms, wk‡	Treatment§	Recurrence
1	39/M	USA	Cervical, mediastinal lymphadenopathy; splenic lesions	Necrotizing granulomatous inflammation (cervical lymph nodes)	11.3	90	20	Meropenem; doxycycline; TMP/SMX; ceftriaxone	Relapse
2	36/M	USA	Cervical, mediastinal, abdominal lymphadenopathy	Necrotizing granulomatous inflammation (perigastric lymph node)	10.2	50	8	TMP-SMX; meropenem; tobramycin; ceftriaxone; doxycycline; cefpodoxime; γ-interferon; tigecycline	Relapse
3	13/M	USA	Cervical, mediastinal, lymphadenopathy	Lymphohistiocytic infiltrate (transtracheal lymph node biopsy specimen)	5.9	44	4	Ceftriaxone; tobramycin; doxycycline; cefdinir	Reinfection
4	17/M	Panama	Cervical, mediastinal lymphadenopathy	Necrotizing granulomatous inflammation (cervical lymph node)	NA	NA	8	Doxycycline	No
5	37/M	USA	Cervical, mediastinal lymphadenopathy; liver and splenic lesions	Necrotizing granulomatous inflammation (supraclavicular lymph node)	7.3	55	16	Ceftriaxone; gentamicin; doxycycline; TMP/SMX; cefdinir	No

*All patients have X-linked chronic granulomatous disease. ESR, erythrocyte sedimentation rate; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available.
†At time of patient visit or diagnosis of Granulibacter spp. infection at the National Institutes of Health, Bethesda, Maryland, USA.
‡From onset of symptoms to culture-confirmed infection; initial symptoms in those with recurrence.
§Drugs used specifically for treatment of G. bethesdensis infection alone or in combination during the patient’s illness. Drugs in boldface were those for which the largest clinical response was observed in that patient.